China launches a “Two-Invoice System” to simplify the drug distribution chain and reduce prices and corruption in the healthcare sector. The new policy may bring substantial compliance and business model challenges for pharmaceutical companies
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
This premium content is reserved for China Law & Practice Subscribers.
Unlimited access to Chinalawandpractice.com site and digital newsletters
5 free articles across the ALM subscription network every 30 days
Exclusive discounts on ALM events and publications
Continue reading by getting started with a subscription.